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Abstract
Breast milk is the only source of the essential amino acid tryptophan (TRP) in breast-fed infants. Low levels of TRP could have implications for infant
neurodevelopment. The objectives of the present study were to compare the relationship of TRP and its neuroactive pathway metabolites kynurenine (Kyn)
and kynurenic acid (KynA) in preterm and term expressed breast milk (EBM) in the ﬁrst 14 d following birth, and the relationship of TRP metabolism to
maternal stress and immune status. A total of twenty-four mothers were recruited from Cork University Maternity Hospital: twelve term (>38 weeks) and
twelve preterm (<35 weeks). EBM samples were collected on days 7 and 14. Free TRP, Kyn and KynA were measured using HPLC, total TRP using MS,
cytokines using the Meso Scale Discovery (MSD) assay system, and cortisol using a cortisol ELISA kit. Although total TRP was higher in preterm EBM in
comparison with term EBM (P < 0·05), free TRP levels were lower (P< 0·05). Kyn, KynA and the Kyn:TRP ratio increased signiﬁcantly in term EBM
from day 7 to day 14 (P < 0·05), but not in preterm EBM. TNF-α, IL-6 and IL-8 were higher in day 7 preterm and term EBM in comparison with day 14.
There were no signiﬁcant differences between term and preterm EBM cortisol levels. Increased availability of total TRP, lower levels of free TRP and
alterations in the temporal dynamics of TRP metabolism in preterm compared with term EBM, coupled with higher EBM inﬂammatory markers on
day 7, may have implications for the neurological development of exclusively breast-fed preterm infants.
Key words: Human milk: Tryptophan: Kynurenine: Kynurenic acid: Cytokines: Cortisol
Breast milk is an excellent source of nutrition for growing
infants due to its numerous bioactive factors such as cytokines,
growth factors and hormones(1). Breast milk continues an
infant’s exposure to the mother’s immune system after birth,
garnering passive immunity(2,3), and playing a primary role in
nurturing and regulating the immature infant immune system(1,2).
Tryptophan (TRP), present in breast milk, is an essential amino
acid that can only be acquired through diet in humans(4), and is
one of the twenty amino acid building blocks required for protein
synthesis(5) in all cells in the body. Most (99 %) of TRP not used
for protein synthesis is metabolised via the kynurenine (Kyn) path-
way(6). Two enzymes, tryptophan 2,3-dioxygenase (TDO) and
Abbreviations: EBM, expressed breast milk; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-γ; KynA, kynurenic acid; Kyn, kynurenine; MSD, Meso Scale Discovery;
QC, quality control; TDO, tryptophan 2,3-dioxygenase; TRP, tryptophan.
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indoleamine 2,3-dioxygenase (IDO), are involved in the Kyn
pathway of TRP metabolism. TDO is primarily a stress-
responsive enzyme(5), while IDO is primarily an immune
responsive enzyme(7–9). Both the TDO and IDO pathways
lead to the production of catabolites Kyn, neuroprotective
kynurenic acid (KynA), and neurotoxic 3-hydroxykynurenine
and quinolinic acid(7).
Maternal serum levels of TRP ﬂuctuate quite considerably,
with the activity of TDO and IDO being tightly regulated
both during and after pregnancy(10). It has been established
that IDO is necessary for the maintenance of pregnancy as
it protects the fetus from T-cell-driven local inﬂammatory
responses(8,10). A study by Schröcksnadel et al.(10) identiﬁed
that maternal serum TRP levels progressively decreased during
pregnancy via immune activation-induced IDO breakdown. In
the postpartum period, though TRP began to rise again, TRP
breakdown in this time period was more primarily triggered by
activation of stress pathways. Of particular note, in the early
peurperium, alterations in TRP catabolites are implicated in
the development of affective symptoms(11).
Cortisol, which is present in breast milk, is a glucocorticoid
that is released under the control of the hypothalamic–pituit-
ary–adrenal axis in a diurnal pattern, with highest levels in
the morning and lowest levels in the evening(12), and is integral
to the correct development of the central nervous system(13).
While antenatal glucocorticoids are vital for normal develop-
ment of the fetus(14), excess secretion due to maternal stress
in pregnancy are strongly associated with preterm birth(15),
and with infant behaviour, mood, cognition and attention
abnormalities in later life(16,17). In the postnatal period, higher
levels of maternal cortisol are associated with fearfulness in
breastfed infants(13). Aside from TRP’s protein synthesis func-
tion, TRP is also the primary precursor for serotonin and
melatonin(18), needed for the regulation of immune responses,
behaviour, mood, appetite, haemodynamics and growth(5).
Cortisol activates the TDO-led breakdown of TRP, leading
directly to a decrease in brain serotonin synthesis(7). Deﬁciencies
in serotonin levels are seen as signiﬁcant causative factors in
the development of anxiety, aggression, affective disorders and
stress syndromes(5). Furthermore, melatonin, the by-product of
serotonin, also found in breast milk, plays a crucial role in stabi-
lising the circadian rhythm of the newborn and consolidation of
the sleep–wake cycle, for optimal development of the brain, and in
immune defence(7,19). Therefore, alterations in TRP have the
potential for neurodevelopmental consequences(7,20).
The relationship dynamic between the serotonin precursor
TRP, its neuroactive pathway metabolites (Kyn and KynA),
immunity and stress has not to our knowledge been previ-
ously investigated in term and preterm expressed breast
milk (EBM). In this study, we hypothesised that higher stress
levels associated with preterm birth would be reﬂected in pre-
term EBM, resulting in increased levels of cortisol and
decreased levels of TRP in comparison with term EBM.
As immune activation is also associated with preterm
labour(21), and as cytokines activate IDO-led breakdown of
TRP down the Kyn metabolite pathway, we also hypothe-
sised that we would ﬁnd higher levels of immune activation
in preterm EBM.
The aims of the study are twofold: (a) compare the relation-
ship of serotonin precursor TRP and its neuroactive pathway
metabolites Kyn and KynA, in preterm and term EBM in the
ﬁrst 14 d following birth; (b) examine the relationship of TRP
to maternal stress (EBM cortisol) and immune status (EBM
cytokines – interferon-γ (IFN-γ), TNF-α, IL-1, IL-6, IL-8)
over the same time-frame.
Methods
This study was conducted in the neonatology department of
the Cork University Maternity Hospital over an 8-week period
from June to July 2013. All mothers received verbal and writ-
ten information about the study and signed a written consent
form before participation. Demographic data were collected
on each mother and baby.
Two specimens of EBM (hind milk) (5–10 ml) were col-
lected from all mothers post-partum, on day 7 and on day
14 from their homes. Every care was taken to ensure that
the timing and collection of the EBM samples were carefully
controlled and consistent. There was only one collecting inves-
tigator who spoke with all mothers either via telephone or in
person the evening before each time point on day 6 and day
13 to ensure they fully understood the process. All samples
were manually expressed after the ﬁrst feed of the day, typically
between 06.00 and 08.00 hours. Of the mothers who provided
EBM samples from home, once the hind-milk sample was
manually expressed into sterile polypropylene containers,
they were instructed to keep the sample in their fridge until
collection by the collecting researcher the same day no later
than 14.00 hours. Any mothers and infants still on the neo-
natal unit used the neonatal sample collection fridge for stor-
age. During transport, the samples were stored in a cooler on
packed ice (±4°C). Limited transportation times were ensured
by placing a 25-mile (40-km) radius restriction for participation
in the study. At the laboratory, all samples were stored initially
at −20°C and then at −80°C until assayed.
The exclusion criteria included maternal use of antibiotics,
maternal mastitis, and mothers living further than a 25-mile
(40-km) radius from the hospital. Five mothers who were ini-
tially recruited onto the study had to be excluded (four
mothers were commenced on antibiotics and one mother
had difﬁculties with breastfeeding). The study was granted eth-
ics approval by the Clinical Research Ethics Committee of the
Cork Teaching Hospitals (reference number of approval: ECM
(IIII) 06/08/13).
Free TRP (TRP bound to/dissociated from albumin) and its
Kyn pathway metabolites were determined using HPLC coupled
to ﬂuorescent and UV detection as previously described(22).
Brieﬂy, EBM samples were spiked with an internal standard
(3-nitro L-tyrosine) prior to the addition of 20 µl of
4 M-perchloric acid to 200 µl of sample. Samples were centri-
fuged at 21 000 g on a Hettich Mikro 22R centrifuge (AGB)
for 20 min at 4°C and 100 µl of supernatant fraction trans-
ferred to an HPLC vial for analysis on the HPLC system
(UV and ﬂuorescence detector detection). All samples were
injected onto a reversed-phase Luna 3 µm C18 (2) 150 × 2
mm column (Phenomenex), which was protected by
2
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Krudkatcher disposable pre-column ﬁlters (Phenomenex) and
Security Guard cartridges (Phenomenex). The mobile phase
consisted of 50 mM-acetic acid, 100 mM-zinc acetate with
3 % (v/v) acetonitrile and was ﬁltered through Millipore
0·45 µm HV Durapore membrane ﬁlters (AGB) and vacuum
degassed prior to use. Compounds were eluted isocratically
over a 30-min runtime at a ﬂow rate of 0·3 ml/min after a
20 µl injection. The column was maintained at a temperature
of 30°C and samples/standards were kept at 8°C in the cooled
autoinjector prior to injection. The ﬂuorescent detector was set
at an excitation wavelength of 254 nm and an emission wave-
length of 404 nm. The UV detector was set to 330 nm. TRP
and its metabolites (Kyn, KynA) were identiﬁed by their char-
acteristic retention times as determined by standard injections
that were run at regular intervals during the sample analysis.
Analyte:internal standard peak height ratios were measured
and compared with standard injections, and results were
expressed as ng of analyte per ml of EBM.
Total TRP (TRP content of EBM protein) in EBM was
determined using GC-MS, which is a modiﬁed version of
the protocol described by Smart et al.(23). A pooled quality con-
trol (QC) sample was created by collecting a small aliquot from
each of the samples. Prior to analysis, all samples were hydro-
lysed by the addition of 4 mM-sodium hydroxide followed by
10 h at 121°C and 5-methyltryptophan was added as an
internal standard. QC samples were hydrolysed individually.
All samples were then derivatised with methyl chloroformate.
The samples were randomised and analysed by GC-MS. The
QC sample was analysed every four to six samples. Testing
of matrix effects was performed by spiking/dilution of QC
samples. It is assumed that the individual samples do not
have matrix effects not found in the QC samples.
A Cortisol ELISA kit (Enzo Life Sciences) was used to
determine the concentration of cortisol in EBM. This tech-
nique has been described for use in human breast milk by
Silva et al.(24). Samples were thawed on ice and centrifuged
at 2000 g for 10 min at 4°C to de-fat the EBM. The aqueous
phase was extracted and used in the ninety-six-well-plate
ELISA assay. Samples were incubated with a solution of alka-
line phosphatase conjugated with cortisol along with a mono-
clonal antibody for cortisol for 2 h at room temperature. The
plate was washed three times in wash solution and incubated
with p-nitrophenyl phosphate substrate solution for 1 h. Stop
solution was applied to each well and the optical density was
read immediately at 405 nm. All samples were run in duplicate,
blanked against the blank wells and their concentration deter-
mined against kit standards. Results are expressed as pg per ml
of sample.
For cytokine analysis, a Meso Scale Discovery (MSD) assay
system was used following a technique previously described
for use in human breast milk by Semba et al.(25). Milk was pre-
pared as described for cortisol assays. Samples were centrifuged
at 2000 g for 10 min at 4°C and the aqueous layer aspirated. A
Human Pro-inﬂammatory II 4-Plex Ultra-Sensitive Kit (MSD)
was used to determine IL-1β, IL-6, IL-8 and TNF-α concentra-
tions in the EBM samples. A Single Spot Human Cytokine
Assay System (MSD) for IFN-γ was also run. Samples and stan-
dards were run in duplicate and the concentration was measured
using the MSD Discovery Workbench® analysis software.
Results are presented in pg per ml of sample.
Statistical analysis was performed using the Graphpad Prism
software package. Data were analysed using two-way repeated-
measures ANOVA (matched pairs only) and two-way
ANOVA (all data points, missing values not replaced)
followed by post hoc analysis (Bonferroni multiple comparisons)
as appropriate. P < 0·05 was considered signiﬁcant. As our
preliminary dataset was not suitable for data imputation, we
provided an analysis restricted to individuals with a complete
dataset and also analysed all data points available to maintain
the power of the analysis and to give a more complete picture
of the data(26). See Supplementary Table S1 for the number of
data points used.
Results
A total of twenty-nine lactating mothers were recruited, of
whom twenty-four successfully completed the study: twelve
mothers with term babies (>38 weeks; term group), and twelve
mothers with preterm babies (<35 weeks; preterm group). The
demographics of mothers and infants, term and preterm, are
presented in Table 1.
Expressed breast milk total and free tryptophan
Total TRP was signiﬁcantly higher in preterm EBM, compared
with term EBM (two-way ANOVA, P < 0·05; Fig. 1). There
were no signiﬁcant differences observed between day 7 and
Table 1. Demographics of mothers and infants
(Mean values, standard deviations and ranges; percentages)
Term group (n 12) Preterm group (n 12)
Mean SD Range Mean SD Range
Maternal age (years) 34·4 3·75 29–44 37·0 7·16 29–44
Parity 1·92 0·9 1–3 1·71 0·5 1–4
Delivery (%)
SVD 67 25
CS 33 75
Gestational age (weeks) 39·7 0·9 38·1–41·7 32·6 1·8 29·0–34·4
Birth weight (kg) 3·5 0·6 2·6–4·3 2·0 0·4 1·4–2·8
SVD, spontaneous vaginal delivery; CS, Caesarean section.
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day 14 samples in preterm or term EBM (P = 0·24 and 0·42,
respectively).
In contrast to total TRP, free TRP levels were signiﬁcantly
lower in preterm EBM compared with term EBM (two-way
ANOVA, P< 0·05; Fig. 2). There was no effect of time on
free TRP concentrations (P> 0·05), nor was there an interaction
between time and group. A post hoc analysis did not indicate any
differences between groups (P> 0·05). A matched-pairs analysis
indicated no signiﬁcant effect of group, time, or interaction
between group and time (P> 0·05).
Expressed breast milk kynurenine
There were no signiﬁcant differences in Kyn levels comparing
term and preterm EBM. However, while mean Kyn levels on day
14 were higher compared with day 7 levels in term EBM (72·5 SE
8·4) v. 22·1 (SE 3·7) ng/ml, two-way ANOVA, P< 0·001; Fig. 3),
the differences were not signiﬁcant in preterm EBM (23·6 (SE
5·7) v. 46·9 (SE 10·5) ng/ml; P > 0·05). While Kyn levels in
term EBM indicated an effect of time (P < 0·001), no effect
of group and no interaction between group and time were
seen (P > 0·05, all data points). A matched-pairs analysis of
Kyn levels in term EBM also highlighted an effect of time
(P < 0·001).
Expressed breast milk kynurenic acid
KynA levels in term EBM indicated an effect of time (P <
0·01) but no effect of group and no interaction between
group and time (P > 0·05, all data points). A matched-pairs
analysis of KynA levels in term EBM also highlighted an effect
of time (P< 0·01). A post hoc analysis indicated that KynA levels
increased signiﬁcantly in term EBM from day 7 to day 14 (10·8
(SE 1·8) v. 41·7 (SE 10·3) ng/ml, two-way ANOVA, P< 0·01;
Fig. 4). The KynA level increase was not signiﬁcant in preterm
EBM from day 7 to day 14 (13·6 (SE 2·6) v. 21·5 (SE 4·7) ng/
ml; P> 0·05).
Fig. 1. Total tryptophan (TRP) in term (-■-) and preterm (- -) expressed breast
milk (EBM) from day 7 to day 14. Results aremeans, with standard errors repre-
sented by vertical bars. See Supplementary Table S1 for the number of data
points used. Total TRP was significantly higher in preterm EBM compared
with term EBM (two-way ANOVA; P < 0·05). * P < 0·05 (two-way ANOVA).
Fig. 2. Free tryptophan (TRP) levels in term (-■-) and preterm (- -) expressed
breast milk (EBM) from day 7 to day 14. Results are means, with standard
errors represented by vertical bars. See Supplementary Table S1 for the num-
ber of data points used. Free TRP levels were significantly lower in preterm
EBM compared with term EBM (P < 0·05). * P < 0·05 (two-way ANOVA).
Fig. 3. Kynurenine (Kyn) levels in term (-■-) and preterm (- -) expressed
breast milk (EBM) on day 7 and day 14. Results are means, with standard
errors represented by vertical bars. See Supplementary Table S1 for the num-
ber of data points used. Kyn levels increased significantly in term EBM from
day 7 to day 14 (P < 0·01); the increase was not significant in preterm EBM
(P > 0·05). ††† P < 0·001 (two-way ANOVA).
Fig. 4. Kynurenic acid (KynA) levels in term (-■-) and preterm (- -) expressed
breast milk (EBM) on day 7 and day 14. Results are means, with standard
errors represented by vertical bars. See Supplementary Table S1 for the num-
ber of data points used. KynA levels increased significantly in term EBM from
day 7 to day 14 (P < 0·01); the increase was not significant in preterm EBM
(P > 0·05). †† P < 0·01 (two-way ANOVA).
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Expressed breast milk kynurenine:tryptophan ratio
An indicator of TRP breakdown, the Kyn:TRP ratio showed
an effect of time (P< 0·01, all data points) but no effect of
group and no interaction between group and time. A matched-
pairs analysis of the Kyn:TRP ratio in term EBM indicated a
trend towards an effect of time (P = 0·05). A post hoc analysis
indicated that the Kyn:TRP ratio increased signiﬁcantly from
day 7 to day 14 in term EBM (0·029 (SE 0·003) v. 0·11 (SE
0·02) ng/ml, two-way ANOVA, P< 0·01; Fig. 5). The Kyn:
TRP ratio increase was not signiﬁcant in preterm EBM
(0·06 (SE 0·02) v. 0·08 (SE 0·01) ng/ml; P> 0·05).
Expressed breast milk free tryptophan:total tryptophan ratio
There was no effect of time, nor was there an interaction
between time and group on the free TRP:total TRP ratio.
There was an overall signiﬁcant difference between the term
and preterm group (two-way ANOVA, P < 0·05; Fig. 6).
The free TRP:total TRP ratio was signiﬁcantly lower in the
preterm EBM (P < 0·05) compared with term EBM.
Expressed breast milk inflammatory markers
There were signiﬁcantly higher levels of TNF-α and IL-8, and
a trend towards elevated IL-6 in both term and preterm EBM
on day 7 compared with day 14 (P < 0·05; Table 2). There was
no effect on group (P > 0·05) and no interaction effect (P>
0·05) on any of the inﬂammatory cytokines (Table 2). Post
hoc analysis indicated that the time-dependent decrease in
these cytokines was not signiﬁcant in either group. There
was no effect of group or time and no interaction between
group and time for other EBM pro-inﬂammatory cytokines
(Table 2).
Expressed breast milk cortisol
There were no differences between term and preterm EBM
levels, with no effect of group or time and no interaction
between group and time for either term or preterm EBM cor-
tisol (Table 2).
Discussion
In the present study, we investigated the supply dynamics of
TRP and its Kyn pathway metabolites (Kyn and KynA), cor-
tisol and cytokines, in paired EBM samples from mothers of
term and preterm infants at two time points post-delivery.
To our knowledge, this is the ﬁrst demonstration showing
that total TRP was found to be signiﬁcantly higher in preterm
EBM compared with term EBM, and preterm EBM contains
less free TRP than term EBM. In addition, TRP metabolites,
Kyn and KynA, have been identiﬁed and quantiﬁed in EBM.
Notably, higher levels of these metabolites were found in term
day 14 EBM compared with term day 7 EBM. Higher levels of
inﬂammatory markers were identiﬁed in term and preterm
EBM on day 7 compared with day 14.
We have noted a reduced availability of free TRP and
increased total TRP concentrations in preterm EBM. This
broad trend is mirrored in the literature where preterm milk
in comparison with term milk is associated with higher protein
content in the early stages of the lactation cycle(27–32). The
increase in total TRP in preterm EBM in the present study
reﬂects the portion that requires processing via digestion but
probably contributes more substantially to circulating TRP avail-
ability on a longer timescale. Of note, 95–99 % of amino acids
in breast milk are contained within proteins(33). Conversely, as
free amino acids in breast milk are more readily absorbed
than protein-derived amino acids, they may be a source of easily
accessible N-containing compounds for the infant; they may
have a role in protecting intestinal growth; and may serve as
functional substrates to nervous tissues(34).
Unlike other amino acids, 90–95 % of free TRP binds pri-
marily to albumin in plasma or serum, while the remainder is
used in its dissociated form for immediate uptake by tissues
and organs(35). Free TRP binding to albumin can be inﬂuenced
Fig. 5. Kynurenine:tryptophan (Kyn:TRP) ratio in term (-■-) and preterm (- -)
expressed breast milk (EBM) on day 7 and day 14. Results are means, with
standard errors represented by vertical bars. See Supplementary Table S1
for the number of data points used. The Kyn:TRP ratio increased significantly
from day 7 to day 14 in term EBM (P < 0·01); the increase was not significant in
preterm EBM (P > 0·05). †† P < 0·01 (two-way ANOVA).
Fig. 6. Free tryptophan (TRP):total TRP ratio in term (-■-) and preterm (- -)
expressed breast milk (EBM) on day 7 and day 14. Results are means, with
standard errors represented by vertical bars. See Supplementary Table S1
for the number of data points used. There was an overall significant difference
between the term and preterm group (P < 0·05). The free TRP:total TRP ratio
was significantly lower in the preterm EBM (P < 0·05) compared with term
EBM. * P < 0·05 (two-way ANOVA).
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by many factors such as hormones, nutrition, pregnancy, drugs
and NEFA(5,35). In this preliminary study, we chose to use
hind milk primarily to avoid interfering with infant feeding(34,36).
Hind milk has a much higher fat content in comparison with
aqueous-rich foremilk(37–39), and, consequently, higher levels
of NEFA which could have an effect on albumin-bound
TRP. However, the dynamic involving albumin-bound TRP is
more important for circulating TRP where albumin is present
in much higher concentrations compared with the relatively
lower albumin levels in breast milk where its physiological
role is less well studied. Our analysis of free TRP in EBM
does not distinguish between the proportion which is bound
and unbound to albumin. This better captures the breast milk
supply of TRP that is not a constituent of protein to the infant
since it is unlikely that TRP would remain associated with albu-
min in the gastrointestinal tract once consumed.
In recognition of the importance of TRP in brain develop-
ment, ESPGHAN coordinated international expert group glo-
bal standard guidelines for the composition of infant
formula(40) recommend that human milk protein composition
should be used as the reference when determining formula
protein composition on the basis that this achieves optimal cir-
culating TRP levels. There are many different kinds of com-
mercial cows’ milk-based formulas available intended for
different periods in life, adapted and follow-on, powdered or
liquid(41,42); full-term infant formulas where proteins can be
intact, hydrolysed or synthetic; preterm formulas with higher
energy density; and specialised formulas, for example exten-
sively hydrolysed protein formulas or formulas with free
amino acids for babies with cows’ milk insensitivity or absorp-
tion issues(42). While human milk contains approximately 114
mg/g N content of TRP(40), it has been found that many regis-
tered formulas have lower mean TRP concentrations than in
breast milk (1–1·5 v. 2·5 %)(43). Comparable circulating plasma
TRP concentrations can be achieved following direct supple-
mentation of formula with TRP(44); however, the static nature
of infant formula is unable to support the development of cir-
cadian rhythms comparable with breast milk(45). Breast milk
TRP demonstrates a nocturnal acrophase, peaking at 03.00
hours and at its lowest level at 15.00 hours in all three stages
of lactation (colostrum, transitional and mature breast
milk)(45).
Breast milk is the only source of the essential amino acid
TRP for exclusively breast-fed infants. TRP is vital for optimal
growth(45), and central nervous system development(27), in
early infancy, and at no other time is structural demand for
TRP higher than in the neonatal period(45). Brain serotonin
synthesis is proportional to the amount of peripheral TRP
available for transport into the brain; thus any decrease in per-
ipheral TRP supply can potentially have an impact on brain
serotonin levels(4,5). An intricate and complex balance exists
between TRP and its Kyn pathway metabolites(7,20). Free
TRP and Kyn readily cross the blood–brain barrier via com-
petitive large amino acid transporters, while KynA, 3-hydroxy-
kynurenine and quinolinic acid cross the blood–brain barrier at
relatively low rates(7,20,46). A high ratio of KynA:3-
hydroxykynurenine and quinolinic acid is associated with low
cognitive performance (e.g. schizophrenia), while a low ratio of
KynA:3-hydroxykynurenine and quinolinic acid is associated
with high neuronal vulnerability (e.g. Huntington’s disease)(20).
Impaired Kyn pathway dysfunction has also been implicated in
major depressive disorder. While there is much speculation over
the complex mechanisms at play, immune system activation of
IDO can result in an increased supply of Kyn to the central ner-
vous system with microglial activation implicated(20) in an increase
in downstream Kyn metabolism and an imbalance in the ratio
between neurotoxic metabolites 3-hydroxykynurenine and quinoli-
nic acid and neuroprotective metabolite KynA(20,47). Other
Table 2. Pro-inflammatory cytokine levels (pg/ml) in term and preterm expressed breast milk (EBM) on day 7 and day 14, and P values for group (G), time
(Ti) and interaction (I)†
(Mean values and standard deviations)
Day 7 Day 14
Group Mean SD Mean SD P
Interferon-γ Term 0·9 0·4 1·4 0·4 0·1 (G)
Preterm 0·3 0·1 0·6 0·2 0·3 (Ti)
0·8 (I)
TNF-α Term 17·2 4·1 9·0 2·3 0·9 (G)
Preterm 13·6 3·8 10·6 3·1 0·03* (Ti)
0·7 (I)
IL-1β Term 18·4 6·1 11·4 4·7 0·6 (G)
Preterm 16·1 8·4 9·3 2·6 0·2 (Ti)
0·8 (I)
IL-6 Term 22·2 5·9 9·1 2·9 0·9 (G)
Preterm 20·6 7·6 9·4 3·5 0·06 (Ti)
0·6 (I)
IL-8 Term 440·2 112·7 267·9 74·8 0·6 (G)
Preterm 384·2 148·3 232·7 73·3 0·03* (Ti)
1·0 (I)
Cortisol Term 3624 572·5 2982 348·9 0·8 (G)
Preterm 3221 1045·0 3793 1018·0 0·9 (Ti)
0·4 (I)
* Significant differences noted.
† See Supplementary Table S1 for the number of data points used.
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Kyn-associated disorders include: HIV-induced dementia, Down’s
syndrome, Alzheimer’s disease, Parkinson’s disease, malignancy,
multiple sclerosis and systemic lupus(6). The implications of low
TRP for the infant appears unclear and underinvestigated in the
literature. In the ﬁrst month of gestation, maternal plasma TRP
is used by the fetus to synthesise serotonin, important for neuro-
development in the forebrain(18). However, disrupted organisation
of the fronto-temporal lobes is one of the most noted ﬁndings in
children with autistic spectrum disorder, and cells from these
patients have been found to be less capable of using TRP as an
energy source(18). In children with attention-deﬁcit disorder,
shorter pregnancies and lower birth weights were associated with
statistically increased levels of 3-hydroxykynurenine and
IFN-γ(48). Whether these low levels of free TRP and its metabol-
ism in preterm EBM are reﬂected in infant plasma levels, and
what effect if any this has on the neurological development of vul-
nerable exclusively breast-fed preterm infants, is an open question.
During pregnancy, while the diurnal secretion of cortisol is
maintained, the regulation of the maternal hypothlamic–pituit-
ary–adrenal axis undergoes major changes, with plasma corti-
sol levels rising to three times non-pregnancy levels largely as a
result of corticotropin-releasing hormone (CRH) release from
the placenta(49,50). In the postpartum period, there is a sharp
drop in placental CRH due to delivery of the placenta, fol-
lowed by a slow recovery of CRH levels by 12 weeks post-
partum, with cortisol levels remaining at normal levels due
to corticosteroid-binding globulin and adrenal gland hyper-
trophy from pregnancy(49). Contrary to our original hypothesis
that the higher stress levels associated with preterm birth
would be reﬂected in preterm EBM, the mothers of preterm
infants did not exhibit elevated levels of stress as indicated
by EBM cortisol concentrations. As cortisol triggers
TDO-led breakdown of TRP down the Kyn metabolite path-
way and because our results showed less free TRP in preterm
EBM, it would have been reasonable to speculate that there
might be higher levels of cortisol in preterm EBM. It should
be noted, however, that using EBM cortisol measures as a
proxy for more validated sources (e.g. plasma or saliva) may
not be ideal and requires further investigation.
While increased amniotic cytokines are associated with pre-
term labour(51), we did not ﬁnd evidence of increased
cytokines in preterm EBM, a pattern also demonstrated by
Ustundag et al.(52). It is important to consider maternal health,
especially in relation to cytokines in the preterm group. The
increased association between preterm labour, advanced
maternal age (≥35 years) and higher Caesarean section
rates(53,54) is reﬂected in our results where mothers who deliv-
ered preterm had higher Caesarean section rates (75 % pre-
term v. 33 % term) and higher rates of advanced maternal
age (37 years preterm v. 34 years term) compared with mothers
who delivered term. The risk factors associated with preterm
birth are numerous and many are immunologically mediated:
inﬂammation, infection, uterine overdistention, uteroplacental
ischaemia or haemorrhage, stress; maternal demographic char-
acteristics, pregnancy history, adverse behaviours, and bio-
logical and genetic markers(55). Nutritional status can have a
large bearing on preterm birth; e.g. low BMI can cause
decreased uterine blood ﬂow and consumption of lower
amounts of vitamins and minerals, whereas obese women
are more likely to have infants with congenital abnormalities
or develop pre-eclampsia and diabetes resulting in preterm
labour(55). The effect of various dietary components which
increase plasma TRP, e.g. protein and carbohydrates(56,57),
are also of major signiﬁcance. Interestingly, dietary supplemen-
tation with either oral L-tryptophan or α-lactalbumin (a protein
high in TRP content) increases the free TRP component of
breast milk but not the total TRP content(33). Maternal diet
thus plays an important role in TRP availability. We cannot,
however, conﬁrm that differences in maternal health and
diet between term and preterm mothers underpin our results
since we did not capture this information in our study.
Limitations
It is possible that lower free TRP levels found in preterm
EBM in our study could be compensated for by infants who
may consume more EBM per kg body weight than their
term counterparts. Infant-weighing studies have demonstrated
signiﬁcant variation with infants nursing anything from eight
to twenty times per d while lactation is being established,
and milk production by the ﬁrst 2 weeks ranging from 480
to 660 ml/d(58).
Measuring serum TRP levels and its metabolites in infant
bloods would address this. However, this was beyond the
scope of the present study. This study was limited to fat-rich
hind-milk EBM investigation but does not provide any infor-
mation on how TRP and its metabolites, cortisol and cytokine
levels vary over the course of the lactation cycle, in particular
foremilk. While we believe there is validity in our single sample
collection point in that it represents a snapshot of the morning
downward ﬂuctuation of TRP in term and preterm EBM, our
data support the future assessment of TRP across its diurnal
cycle to see if the differences we have noted are sustained
over a longer period. The same is true of diurnal variations
of cortisol. EBM might not be the best biological source to
use as a predictive weathervane when looking at maternal
stress and immune status. Maternal plasma TRP levels were
not measured. Consequently, it was not possible to determine
if the TRP and metabolite concentrations present in EBM are
a consequence of enzymic activity in the breast itself or are
reﬂective of circulating maternal serum concentration.
Similarly, as we did not have access to infant plasma samples,
it was not possible to determine if altered TRP and Kyn
metabolite supply translated into altered circulating availability
in the infant. Once these valuable, difﬁcult-to-acquire samples
are harvested, it will also be important to establish the extent
to which the free TRP concentration in EBM reported here
contributes to circulating levels relative to the proportion
derived from breast milk proteins. We did not control for
the impact of maternal dietary TRP on breast milk or maternal
health in our study; thus this warrants investigation in all future
work. Measuring anti-inﬂammatory markers in future studies
would also provide further valuable data on the inﬂammatory
processes at play in breast milk. Finally, breast milk is widely
recognised as being notoriously difﬁcult to examine due to
its ‘biochemical complexity’, the small concentration of many
7
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of its bioactive components, and the fact that it exhibits many
dynamic and qualitative changes(2), including circadian
rhythms(19,43). The small number of EBM samples taken at
only one time point each day in this exploratory study may
have impaired our ability to reliably detect group differences
of these bioactive components, if they exist.
Implications and recommendations
If the dynamics of free and total TRP are replicated and vali-
dated in larger studies, future research would be needed to estab-
lish the merits of matching full term complement of TRP and
its metabolites to preterm EBM. Future research should also
set out to identify the EBM metabolite proﬁle downstream of
Kyn production along the neurotoxic arm of the pathway.
Clearly, if neurotoxic metabolites such as 3-hydroxykynurenine
and quinolinic acid are also present in breast milk in addition
to KynA, the relevance for the vulnerable infant central ner-
vous system needs to be established. Further research would
be valuable in examining the hypothesis that TRP and its
metabolites present in breast milk could play a nurturing and
regulating function on the immature TRP and Kyn pathways
in the infant. Combining EBM cortisol analysis with maternal
and infant serum, saliva samples, and validated rating scales to
capture the self-reported stress status of the mothers, in con-
junction with morning and evening EBM samples should be
incorporated into future studies arising from this work.
Before any practical conclusions and recommendations can
be considered, additional studies are needed to conﬁrm or
reject our observations and hypothesis.
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/jns.2017.69
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